Sacroiliitis Treatment Global Market Report 2025

The sacroiliitis treatment market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. This growth during the historical period was fueled by the increasing prevalence of lower back pain, a growing emphasis on early diagnosis, a surge in pelvic injuries from sports, greater use of advanced imaging methods, and a heightened preference for minimally invasive treatment options.

The sacroiliitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth will be supported by greater investment in R&D for innovative therapies, the rising use of telehealth services in managing chronic pain, increasing occurrences of autoimmune disorders, broader access to biologic therapies targeting specific pathways, and a growing emphasis on personalized medical treatments. Prominent trends anticipated in this period include innovations in targeted drug delivery, emergence of customized treatment regimens, progress in regenerative therapy solutions, improvements in robotic-assisted surgical techniques, and the evolution of integrated treatment protocols.

The rising number of joint disorders is expected to drive the growth of the sacroiliitis treatment market. Joint disorders, which include conditions causing pain, inflammation, stiffness, and limited movement in the joints, are often due to factors such as aging, injury, autoimmune diseases, or infections. As populations age, there is a natural increase in wear and tear on joints, leading to a greater prevalence of conditions like osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment plays a crucial role in managing joint disorders by reducing inflammation and pain in the sacroiliac joints, thereby improving mobility and joint function, which helps alleviate symptoms and prevent further damage. For example, in June 2024, the Australian Institute of Health and Welfare reported that osteoarthritis affected an estimated 2.1 million Australians (8.3%) in 2022, including 10% of women and 6.1% of men. This growing incidence of joint disorders is contributing to the expansion of the sacroiliitis treatment market.

Companies in the sacroiliitis treatment market are prioritizing regulatory approvals to facilitate the introduction of innovative therapies, ensure market access, and reinforce their competitive positions. Regulatory approvals signify formal authorization by government health agencies, confirming that a medical treatment is safe and effective for public use. In December 2023, Spinal Simplicity, a US-based medical equipment manufacturer, received FDA 510(k) clearance for its Liberty-SI Lateral Implant System. This system is a minimally invasive device designed for sacroiliac joint fusion in patients with conditions such as sacroiliac disruptions and degenerative sacroiliitis. It employs a lateral approach by inserting one or two titanium implants through the ilium and across the SI joint into the sacrum, providing stabilization and fusion. These implants have a central threaded body with deployable wings and compressive elements, come in various sizes, and are coated with hydroxyapatite to enhance bone integration. The system is designed to be less invasive, potentially shortening anesthesia time and improving patient outcomes.

In November 2023, Nevro Corp., a US-based medical device company focused on pain management solutions, acquired Vyrsa Technologies for an undisclosed amount. This acquisition is intended to enhance Nevro’s portfolio of minimally invasive treatments and accelerate the adoption and development of Vyrsa’s advanced spinal technologies by leveraging Nevro’s commercial infrastructure and clinical expertise. Vyrsa Technologies is a US-based medical device firm that provides a minimally invasive treatment option for sacroiliitis, specifically concentrating on sacroiliac joint fusion.

Major players in the sacroiliitis treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Biogen Inc., Sandoz Group AG, UCB S.A., Hikma Pharmaceuticals PLC, Samsung Bioepis Co. Ltd., Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co. Ltd., Torrent Pharmaceuticals Limited, Globus Medical, Fortis Healthcare, Orthofix Medical Inc., Coherus BioSciences Inc., and SI-BONE Inc.

North America was the largest region in the sacroiliitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sacroiliitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sacroiliitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Sacroiliitis treatment refers to the healthcare interventions used to address inflammation in one or both of the sacroiliac joints, which connect the lower spine to the pelvis. This condition often leads to pain in the lower back, buttocks, or legs and is frequently linked to inflammatory disorders such as ankylosing spondylitis. The main objective of sacroiliitis treatment is to alleviate inflammation, reduce pain, and improve mobility.

Key treatment options for sacroiliitis include medications, joint injections, joint fusion surgery, radiofrequency denervation, and electrical stimulation. Medications primarily involve nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics that are effective in easing inflammation and pain in the sacroiliac region. Diagnosis involves various methods such as imaging tests, physical exams, and laboratory diagnostics. These treatments are delivered through oral, injectable, or topical routes and are utilized in diverse settings including hospitals, specialty clinics, ambulatory surgical centers, and home care facilities.

The sacroiliitis treatment market research report is one of a series of new reports that provides sacroiliitis treatment market statistics, including sacroiliitis treatment industry global market size, regional shares, competitors with a sacroiliitis treatment market share, detailed sacroiliitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the sacroiliitis treatment industry. This sacroiliitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sacroiliitis treatment market includes revenues earned by entities by providing services, such as anti-inflammatory medications, pharmacological treatment, physical therapy, interventional pain management, surgical services, and chiropractic and osteopathic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.